Effect of ABCG2/BCRP expression on efflux and uptake of Gefitinib in NSCLC cell lines

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Galetti, Maricla ^a   Petronini, Pier Giorgio ^a   Fumarola, Claudia ^a   Cretella, Daniele ^a   La Monica, Silvia ^a   Bonelli, Mara ^a   Cavazzoni, Andrea ^a   Saccani, Francesca ^a   Caffarra, Cristina ^a   Andreoli, Roberta ^a   Mutti, Antonio ^a   Tiseo, Marcello ^b   Ardizzoni, Andrea ^c   Alfieri, Roberta R ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; GEFITINIB; GLUTAMINE; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SMALL INTERFERING RNA; TRYPTOQUIVALINE; TUMOR PROTEIN;

A549 CELL LINE; ARTICLE; BIOACCUMULATION; CALU 1 CELL LINE; CANCER CELL LINE; CELL MEMBRANE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG TRANSPORT; GLUCOSE TRANSPORT; H1299 CELL LINE; H292 CELL LINE; H460 CELL LINE; HCC827 CELL LINE; HUMAN; HUMAN CELL; NON SMALL CELL LUNG CANCER; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LUNG TUMOR; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TANDEM MASS SPECTROMETRY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 2; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; INDOLES; LUNG NEOPLASMS; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; TANDEM MASS SPECTROMETRY;

EID: 84951045861     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141795     Document Type: Article

References (45)

1. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003; 55 (1): 3-29. PMID: 12535572
2. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 1999; 59 (1): 8-13. PMID: 9892175
3. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998; 95 (26): 15665-70. PMID: 9861027
4. Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T, et al. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer. 2002; 97 (5): 626-30. PMID: 11807788
5. Xu J, Liu Y, Yang Y, Bates S, Zhang JT. Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem. 2004; 279 (19): 19781-9. PMID: 15001581
6. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001; 61 (8): 3458-64. PMID: 11309308
7. Noguchi K, Katayama K, Sugimoto Y. Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. Pharmgenomics Pers Med. 2014; 7: 53-64. doi: 10.2147/PGPM.S38295 PMID: 24523596
8. Shukla S, Chen ZS, Ambudkar SV. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resist Updat. 2012; 15 (1-2): 70-80. doi: 10.1016/j.drup.2012.01.005 PMID: 22325423
9. Brozik A, Hegedus C, Erdei Z, Hegedus T, Ozvegy-Laczka C, Szakacs G, et al. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin Drug Metab Toxicol. 2011; 7 (5): 623-42. doi: 10.1517/17425255.2011.562892 PMID: 21410427
10. Wang XK, Fu LW. Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins. Curr Drug Metab. 2010; 11 (7): 618-28. PMID: 20812904
11. Yang K, Fu LW. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review. Crit Rev Oncol Hematol. 2015; 93 (3): 277-92. doi: 10.1016/j.critrevonc.2014.11.001 PMID: 25500000
12. Wang YJ, Zhang YK, Kathawala RJ, Chen ZS. Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance. Cancers (Basel). 2014; 6 (4): 1925-52.
13. Anreddy N, Gupta P, Kathawala RJ, Patel A, Wurpel JN, Chen ZS. Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance. Molecules. 2014; 19 (9): 13848-77. doi: 10. 3390/molecules190913848 PMID: 25191874
14. Kathawala RJ, Gupta P, Ashby CR Jr., Chen ZS. The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resist Updat. 2015; 18: 1-17. doi: 10. 1016/j.drup.2014.11.002 PMID: 25554624
15. Hegedus C, Ozvegy-Laczka C, Szakacs G, Sarkadi B. Interaction of ABC multidrug transporters with anticancer protein kinase inhibitors: substrates and/or inhibitors? Curr Cancer Drug Targets. 2009; 9 (3): 252-72. PMID: 19442047
16. Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD. Kinase switching in mesenchymal-like nonsmall cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis. 2008; 25 (8): 843-54. doi: 10.1007/s10585-008-9200-4 PMID: 18696232
17. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011; 3 (75): 75ra26. doi: 10.1126/scitranslmed.3002003 PMID: 21430269
18. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19 (8): 2240-7. doi: 10.1158/1078-0432.CCR-12-2246 PMID: 23470965
19. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol. 2004; 65 (6): 1485-95. PMID: 15155841
20. Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther. 2007; 6 (3): 432-8. PMID: 17312388
21. Chen YJ, Huang WC, Wei YL, Hsu SC, Yuan P, Lin HY, et al. Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS One. 2011; 6 (6): e21428. doi: 10.1371/journal.pone.0021428 PMID: 21731744
22. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, et al. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res. 2004; 64 (20): 7491-9. PMID: 15492275
23. Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther. 2004; 3 (9): 1119-25. PMID: 15367706
24. Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, Whang-Peng J, et al. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res. 2005; 65 (15): 6943-9. PMID: 16061679
25. Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, et al. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ ABCG2-mediated drug resistance. Cancer Res. 2005; 65 (4): 1541-6. PMID: 15735043
26. Nagashima S, Soda H, Oka M, Kitazaki T, Shiozawa K, Nakamura Y, et al. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol. 2006; 58 (5): 594-600. PMID: 16520985
27. Wang Z, Pal D, Patel A, Kwatra D, Mitra AK. Influence of overexpression of efflux proteins on the function and gene expression of endogenous peptide transporters in MDR-transfected MDCKII cell lines. Int J Pharm. 2013; 441 (1-2): 40-9. doi: 10.1016/j.ijpharm.2012.12.011 PMID: 23262422
28. Galetti M, Alfieri RR, Cavazzoni A, La Monica S, Bonelli M, Fumarola C, et al. Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines. Biochem Pharmacol. 2010; 80 (2): 179-87. doi: 10.1016/j.bcp.2010.03.033 PMID: 20363215
29. Alfieri RR, Galetti M, Tramonti S, Andreoli R, Mozzoni P, Cavazzoni A, et al. Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines. Mol Cancer. 2011; 10: 143. doi: 10.1186/1476-4598-10-143 PMID: 22111840
30. Petronini PG, Alfieri RR, Losio MN, Caccamo AE, Cavazzoni A, Bonelli MA, et al. Induction of BGT-1 and amino acid system A transport activities in endothelial cells exposed to hyperosmolarity. Am J Physiol Regul Integr Comp Physiol. 2000; 279 (5): R1580-9. PMID: 11049839
31. Alfieri RR, Bonelli MA, Cavazzoni A, Brigotti M, Fumarola C, Sestili P, et al. Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress. J Physiol. 2006; 576 (Pt 2): 391-401. PMID: 16873409
32. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer. 2003; 89 (10): 1971-8. PMID: 14612912
33. Cavazzoni A, Alfieri RR, Carmi C, Zuliani V, Galetti M, Fumarola C, et al. Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines. Mol Cancer Ther. 2008; 7 (2): 361-70. doi: 10.1158/1535-7163.MCT-07-0477 PMID: 18281519
34. Cavazzoni A, Alfieri RR, Cretella D, Saccani F, Ampollini L, Galetti M, et al. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines. Mol Cancer. 2012; 11: 91. doi: 10.1186/1476-4598-11-91 PMID: 23234355
35. Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, et al. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res. 2002; 8 (1): 22-8. PMID: 11801536
36. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72: 248-54. PMID: 942051
37. Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther. 2010; 334 (1): 147-55. doi: 10.1124/jpet.110.167601 PMID: 20421331
38. Leggas M, Panetta JC, Zhuang Y, Schuetz JD, Johnston B, Bai F, et al. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res. 2006; 66 (9): 4802-7. PMID: 16651435
39. Pan G, Winter TN, Roberts JC, Fairbanks CA, Elmquist WF. Organic cation uptake is enhanced in bcrp1-transfected MDCKII cells. Mol Pharm. 2010; 7 (1): 138-45. doi: 10.1021/mp900177r PMID: 19886673
40. Elkind NB, Szentpetery Z, Apati A, Ozvegy-Laczka C, Varady G, Ujhelly O, et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res. 2005; 65 (5): 1770-7. PMID: 15753373
41. Lemos C, Kathmann I, Giovannetti E, Calhau C, Jansen G, Peters GJ. Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib. Br J Cancer. 2009; 100 (7): 1120-7. doi: 10.1038/sj.bjc.6604980 PMID: 19277036
42. Huang Y, Sadee W. Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett. 2006; 239 (2): 168-82. PMID: 16169662
43. Li X, Kamenecka TM, Cameron MD. Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. Chem Res Toxicol. 2009; 22 (10): 1736-42. doi: 10.1021/tx900256y PMID: 19803472
44. Stam RW, van den Heuvel-Eibrink MM, den Boer ML, Ebus ME, Janka-Schaub GE, Allen JD, et al. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. Leukemia. 2004; 18 (1): 78-83. PMID: 14574327
45. Hadnagy A, Gaboury L, Beaulieu R, Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res. 2006; 312 (19): 3701-10. PMID: 17046749